Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to email@example.com so that we can defer those challenges. Your health and safety are paramount to us.
Posted 06 July 2012
The European Medicines Agency (EMA) has two messages for applicants of marketing authorization applications: please submit all applications electronically, and don't forget to submit labeling translations to Croatian regulatory authorities.
In a statement released 5 July, EMA said it is imploring sponsors of pharmaceutical products to start taking advantage of its electronic application forms, including its eSubmission Gateway, due to its relative ease of use. The agency also highlighted its advantages in advance of the Olympics, which will be taking place around EMA's offices and may impact the delivery of paper applications or CD/DVD-based applications. EMA has already canceled nearly a dozen of its meetings due to the anticipated traffic situation in London.
To assist sponsors who have not yet utilized the electronic submission system, EMA said it will offer "enhanced support" until the end of July 2012.
In a separate statement, also released 5 July 2012, EMA said it is reminding sponsors to submit Croatian translations of product information in advance of Croatia's July 2013 entry into the EU.
"This process enables the Croatian authorities to review product information in Croatian in advance of the country's accession," EMA explained. "Its aim [is] to facilitate the phasing-in of Commission decisions related to the EU centralised procedure and to avoid delays of supply of relevant medicinal products in Croatia after EU enlargement."
Because the pace of product reviews by Croatian regulatory authorities has thus far been "slow"-only 90 products have thus far undergone review-EMA is advising sponsors to submit their translations for their products early to avoid "delays in the checking process."
EMA was also clear to say that "no extension of the pre-accession linguistic review process (PALC III) will be granted" and "cannot be extended."
"Any product that does not go through the PALC III process will be handled after Croatia's accession in the normal linguistic review process. This means that the Croatian national competent authority will need more time for the linguistic check, resulting in delays in the decision-making process for the product as a whole," noted EMA.
Tags: PALC III, Croatia, Olympics, eSubmission, Latest News, eCTD, translation
Regulatory Focus newsletters
All the biggest regulatory news and happenings.